TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05822869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EIT-guided mechanical ventilation strategy
Description: During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lung protective ventilation group
Description: Lung-protective ventilation strategy during prone positioning that continues the supine position.
Study: NCT05089227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment intervention
Description: for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment standard
Description: during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
Study: NCT05089565

Intervention type: DIAGNOSTIC_TEST
Intervention: Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
Description: Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination

Intervention type: DIAGNOSTIC_TEST
Intervention: Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
Description: Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination

Intervention type: DIAGNOSTIC_TEST
Intervention: Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
Description: Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination
Study: NCT05926206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devimistat
Description: Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devimistat
Description: Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devimistat
Description: Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
Study: NCT05136391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTR003
Description: Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
Study: NCT04676243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: 20 mg coated tablets, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment according to Physician's Choice
Description: Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
Study: NCT03528681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate 5g
Description: Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate 10g
Description: Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Study: NCT05290467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online antenatal care
Description: ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
Study: NCT06394622

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells
Description: Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
Study: NCT04837404

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided femoral access for complex PCI
Description: Ultrasound guided femoral access for complex PCI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fluoroscopy guided femoral access for complex PCI
Description: Fluoroscopy guided femoral access for complex PCI
Study: NCT05089227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological assessment
Description: CBC, reticulocytes, haptoglobin, LDH, bilirubin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biological assessment
Description: CBC, reticulocytes, haptoglobin, LDH, bilirubin
Study: NCT04895436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous (IV) infusion
Study: NCT06008379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7MW3711 for injection
Description: IV administration of 7MW3711, Q3W, 3 weeks a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7MW3711 for injection
Description: IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
Study: NCT06152354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rotary system
Description: crown down technique using Kedo-SG file rotary system using endodontic motor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual files
Description: instrumentation were done by step back technique using K- file (Mani ) from size 15 to size 35 in quarter pull turn motion apically
Study: NCT06464406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality condition
Description: Participants will watch a video on a virtual reality headset during the completion of the maximal cardiorespiratory exercise test.
Study: NCT06210295

Intervention type: COMBINATION_PRODUCT
Intervention: Laboratory investigtions
Description: To study causes of anemia in SLE in our environment and causes of refractory type and its relation to bone marrow affection and different drugs used in SLE
Study: NCT05313464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parent-pushed enteral feeding
Description: skin-to-skin enteral nutrition pushed by the parent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: syringe-push enteral feeding
Description: skin to skin nutrition with syringe pump
Study: NCT04895436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous (IV) infusion
Study: NCT06171178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion
Study: NCT06464406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality condition
Description: Participants will watch a video on a virtual reality headset during the completion of the maximal cardiorespiratory exercise test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Participants will complete the maximal cardiorespiratory exercise test under control conditions without video, music, or other distractions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Participants will complete the maximal cardiorespiratory exercise test under control conditions without video, music, or other distractions.
Study: NCT05195359

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore
Description: The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
Study: NCT06171178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion
Study: NCT03835338

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation
Description: Pulmonary Vein Isolation by RF Ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation
Description: Pulmonary Vein Isolation by RF Ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAA Isolation
Description: LAA Isolation by RF Ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAA Occlusion
Description: LAA Occlusion by implantation of the WATCHMAN LAAC Device
Study: NCT04886765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALMB-0168
Description: ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Study: NCT04723069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Group
Description: metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Group
Description: metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
Study: NCT06122493

Intervention type: DRUG
Group type: OTHER
Intervention: Tirelizumab
Description: immunotherapy, 200 mg on day 1 per 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Nab paclitaxel
Description: chemotherapy, 175 mg/m² on day 1 per 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: chemotherapy, AUC=5 on day 1 per 3 weeks

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.
Study: NCT05326100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy (CPT)
Description: The exercises may include traditional vestibulo-ocular reflex (VOR) exercises, cervical musculoskeletal exercises, somatosensory exercises, habituation, gait exercises, and aerobic conditioning. The treating PT will modify specific exercises as appropriate based on the participant's symptoms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAREN Therapy
Description: The CAREN, an FDA-registered exempted Class I device, is a VR-based system which includes a six degree-of-freedom motion platform with an embedded, instrumented treadmill surrounded by an immersive 180-degree screen. The CAREN can display a variety of virtual environments (VEs), where the difficulty level and task requirements can be easily modified by the treating clinician to target patient-specific needs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) Therapy
Description: AR head-mounted displays are designed to provide immersive virtual environments similar to the CAREN, but with the portability to be used in most outpatient clinical settings and potentially for at-home therapy as well as significantly reduced cost compared to the CAREN. AR devices have integrated eye-tracking and inertial measurement units (IMUs) which can be used to objectively quantify characteristics of eye, head and body movement.
Study: NCT05277259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
Study: NCT04934202

Intervention type: OTHER
Intervention: Teleconsultation
Description: Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:~* General signs: Anorexia, fatigue, new hospitalization, weight loss,~* Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge~* Neurological signs: headache, paraesthesia, anosmia, limb paralysis~* Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting~Edition 2021~◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties
Study: NCT05277259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Elastic band to be used to stretch the upper trapezius muscle in the desired direction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional physical therapy will be consisted of hotpack, therapeutic ultrasound and tens applications.
Study: NCT04947904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of the patient's fluid intake during the first 7 days
Description: The volume of fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in the intensive care unit according to a protocol with instructions to reduce fluid intake as far as possible in terms of maintenance fluids, dilution of medication and artificial nutrition. This protocol will be begun immediately following the patient's inclusion on Day 1 and pursued for 7 days after inclusion (i.e. from Day 1 - to Day 7). The fluid restriction strategy does not involve the administration of any medication (i.e. diuretics). A clinical pharmacist will help the intensive care teams apply the fluid restriction protocol with a daily check. If the restrictive strategy leads to hypovolemia and / or a electrolyte anomaly (sodium, potassium, chloride, etc.), the physician in charge will be authorised to treat these anomalies in conformance with the protocol recommendations.
Study: NCT04934202

Intervention type: OTHER
Intervention: Teleconsultation
Description: Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:~* General signs: Anorexia, fatigue, new hospitalization, weight loss,~* Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge~* Neurological signs: headache, paraesthesia, anosmia, limb paralysis~* Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting~Edition 2021~◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties

Intervention type: OTHER
Intervention: Outpatient clinic
Description: During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.~* General clinical examination~* Assessment of the state of health~* Respiratory assessment~* Pulmonary CT assessment~* Cognitive evaluation~* Cardiological evaluation~* Renal assessment~* Immunological evaluation

Intervention type: OTHER
Intervention: Outpatient clinic
Description: During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.~* General clinical examination~* Assessment of the state of health~* Respiratory assessment~* Pulmonary CT assessment~* Cognitive evaluation~* Cardiological evaluation~* Renal assessment~* Immunological evaluation
Study: NCT04831450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: 350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
Study: NCT06075290

Intervention type: BEHAVIORAL
Intervention: internet plus model
Description: Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up

Intervention type: BEHAVIORAL
Intervention: control
Description: follow-up by conventional methods; hospital or community follow-up depending on arrangement
Study: NCT05509621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Supine Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns
Description: Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns
Description: Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
Study: NCT05011552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion, Health, and Empowerment (SHE)
Description: The SHE intervention includes 8 weekly sessions and 24-hour access to the intervener for any additional support needed. The first and last sessions will be delivered over the phone with the woman based on a brochure. The brochure describes the four major components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources. It will be discussed with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Session 2-7 focus on providing mental health self-care resources, which are deep breathing, progressive muscle relaxation, visualization, general introduction and overview of self-compassion, mindfulness, and loving-kindness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Control Condition
Description: Women randomized to the control group will be provided with the same brochure and mental health care resources.